InMed Pharmaceuticals: Pushing Pharma Forward With Rare Cannabinoids

Jerry Griffin, VP of Sales & Marketing at BayMedica, Inc. – a subsidiary of InMed Pharmaceuticals Inc INM – was a guest on Benzinga’s All Access.

InMed is a clinical stage biopharma company that develops drugs based on rare cannabinoids. The company has several drugs in the development pipeline that target ailments as diverse as glaucoma and neurodegenerative diseases.

The company’s subsidiary, Baymedica, produces synthetic cannabinoids for the health and wellness sector. 

Watch the full interview here:

Featured photo by Hans Reniers on Unsplash

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechCannabisPenny StocksMarketsGeneralBenzinga All AccessInMed Pharmaceutics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.